Cytox Ltd, a Harwell, Oxon, UK-based developer of assays for risk assessment and prediction of dementia, closed a £1.5m second round of funding.
Backers included new shareholder Seneca Partners, existing shareholders SPARK, Northwest Fund for Biomedical, Wren Capital and The Rainbow Seed Fund (Midven), and private investors.
The company, which had raised £3.5 in May 2013, intends to use the funds to extend its clinical research program and access potentially valuable utility claims.
Led by Dr. Richard Pither, CEO, Cytox is researching into the role of mTOR pathway dysfunction and the associated development of prognostic tests for cognitive decline and risk of developing AD or other dementias.
The company has exclusive rights to build on the discoveries made by its scientific founder, Dr. Zsuzsanna Nagy, of cell cycle-related biomarkers associated with the risk of developing dementia. The company is developing her work and assessing its significance in trials and will be looking to work with pharmaceutical partners to develop our understanding of the technology and its role in drug development.
It has a partnership with a US-based laboratory Selah Genomics.